Body & brain: Antibody may stop leukemia early: Molecular approach shows promise against blood cancer

The Proclossiana eunomia (Esper, 1799) complex is currently composed of the several subspecies distributed throughout Palaearсtic region and North America. Despite the fact that some of the taxa have differences in wing pattern and body size, previous assumptions on taxonomy not supported by molecular data. Therefore, the identity of certain populations of this complex has remained unclear and the taxonomic status of several recently described taxa is debated. Here, we provide insights into systematics of some Palaearctic members of this group using molecular approach, based on the analysis of the barcoding fragment of the COI gene taking into account known morphological differences.

Download Full-text

FDA approves first treatment for certain patients with Erdheim-Chester Disease, a rare blood cancer

Case Medical Research ◽

10.31525/cmr-29dd739 ◽

2018 ◽

Author(s):

Keyword(s):

Blood Cancer ◽

Erdheim Chester Disease ◽

Erdheim Chester ◽

Chester Disease

Download Full-text

Molecular Approach to Hypothalamic Rhythms

10.21236/ada348785 ◽

1998 ◽

Author(s):

J. G. Sutcliffe

Keyword(s):

Molecular Approach

Download Full-text

A Molecular Approach for Metatastic Progression of Breast Cancer

10.21236/ada419679 ◽

2003 ◽

Author(s):

Ratna K. Vadlamudi

Keyword(s):

Breast Cancer ◽

Molecular Approach

Download Full-text

Combination of nuclear and mitochondrial markers as a useful tool to identify Ctenophthalmus species and subspecies (Siphonaptera: Ctenophthalmidae)

Organisms Diversity & Evolution ◽

10.1007/s13127-021-00500-4 ◽

2021 ◽

Author(s):

Antonio Zurita ◽

Cristina Cutillas

Keyword(s):

Taxonomic Status ◽

Molecular Study ◽

Molecular Data ◽

Point Of View ◽

Morphological Data ◽

Molecular Approach ◽

Nuclear Marker ◽

Mitochondrial Markers ◽

Morphological Criteria ◽

Mtdna Markers

AbstractCtenophthalmus is considered the largest genus within the Order Siphonaptera. From a morphological point of view, only males of this genus can be identified at species and subspecies levels using morphological keys, whereas there are no morphological criteria in order to classify females at these taxonomical levels. Furthermore, the amount of available molecular and phylogenetic data for this genus is quite scarce so far. The main objective of this work was to assess the utility of the combination of nuclear and mitochondrial markers with respect to their ability to differentiate among different subspecies within the Ctenophthalmus genus. With this purpose, we carried out a comparative morphological and molecular study of three different subspecies (Ctenophthalmus baeticus arvernus, Ctenophthalmus nobilis dobyi, and Ctenophthalmus andorrensis catalaniensis) in order to clarify and discuss its taxonomic status. In addition, our study complemented the molecular data previously provided for Ctenophthalmus baeticus boisseauorum and Ctenophthalmus apertus allani subspecies. We sequenced five different molecular markers: EF1-α, ITS1, ITS2, cox1, and cytb. Our results confirmed that morphological data by themselves are not able to discriminate among Ctenophthalmus female taxa; however, the combination of the nuclear marker EF1-α together with mtDNA markers cytb and cox1 constituted a useful taxonomical and phylogenetic tool to solve this issue. Based on these results, we consider that the use of this molecular approach should be gradually used within Ctenophthalmus genus in order to complement its classical taxonomy and clarifying the complex taxonomy of other congeneric species of fleas.

Download Full-text

A Bird’s-Eye View of Cell Sources for Cell-Based Therapies in Blood Cancers

Cancers ◽

10.3390/cancers12051333 ◽

2020 ◽

Vol 12 (5) ◽

pp. 1333

Author(s):

Benjamin Motais ◽

Sandra Charvátová ◽

Matouš Hrdinka ◽

Michal Šimíček ◽

Tomáš Jelínek ◽

...

Keyword(s):

Hematological Malignancies ◽

Antigen Receptors ◽

Chimeric Antigen Receptors ◽

Blood Cancer ◽

Cell Based Therapy ◽

Cell Source ◽

Different Types ◽

Cell Sources ◽

The One ◽

Initial Results

Hematological malignancies comprise over a hundred different types of cancers and account for around 6.5% of all cancers. Despite the significant improvements in diagnosis and treatment, many of those cancers remain incurable. In recent years, cancer cell-based therapy has become a promising approach to treat those incurable hematological malignancies with striking results in different clinical trials. The most investigated, and the one that has advanced the most, is the cell-based therapy with T lymphocytes modified with chimeric antigen receptors. Those promising initial results prepared the ground to explore other cell-based therapies to treat patients with blood cancer. In this review, we want to provide an overview of the different types of cell-based therapies in blood cancer, describing them according to the cell source.

Download Full-text

A molecular approach to the synthesis of platinum-decorated mesoporous graphitic carbon nitride as selective CO2 reduction photocatalyst

Journal of CO2 Utilization ◽

10.1016/j.jcou.2021.101574 ◽

2021 ◽

Vol 50 ◽

pp. 101574

Author(s):

Minoo Tasbihi ◽

Fernando Fresno ◽

Ignacio Álvarez-Prada ◽

Amitava Acharjya ◽

Arne Thomas ◽

...

Keyword(s):

Carbon Nitride ◽

Co2 Reduction ◽

Graphitic Carbon ◽

Graphitic Carbon Nitride ◽

Molecular Approach

Download Full-text

The “Vesicular Intelligence” Strategy of Blood Cancers

Genes ◽

10.3390/genes12030416 ◽

2021 ◽

Vol 12 (3) ◽

pp. 416

Author(s):

Dorian Forte ◽

Martina Barone ◽

Francesca Palandri ◽

Lucia Catani

Keyword(s):

Clonal Evolution ◽

Biological Properties ◽

Hemopoietic Stem Cell ◽

Target Cells ◽

Cancer Cell Growth ◽

Cell Compartment ◽

Blood Cancer ◽

Non Invasive ◽

Membrane Bound ◽

Immune Potential

Blood cancers are a heterogeneous group of disorders including leukemia, multiple myeloma, and lymphoma. They may derive from the clonal evolution of the hemopoietic stem cell compartment or from the transformation of progenitors with immune potential. Extracellular vesicles (EVs) are membrane-bound nanovesicles which are released by cells into body fluids with a role in intercellular communication in physiology and pathology, including cancer. EV cargos are enriched in nucleic acids, proteins, and lipids, and these molecules can be delivered to target cells to influence their biological properties and modify surrounding or distant targets. In this review, we will describe the “smart strategy” on how blood cancer-derived EVs modulate tumor cell development and maintenance. Moreover, we will also depict the function of microenvironment-derived EVs in blood cancers and discuss how the interplay between tumor and microenvironment affects blood cancer cell growth and spreading, immune response, angiogenesis, thrombogenicity, and drug resistance. The potential of EVs as non-invasive biomarkers will be also discussed. Lastly, we discuss the clinical application viewpoint of EVs in blood cancers. Overall, blood cancers apply a ‘vesicular intelligence’ strategy to spread signals over their microenvironment, promoting the development and/or maintenance of the malignant clone.

Download Full-text